PepGen Inc. announced positive initial clinical data from the 5 mg/kg and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial. This trial is investigating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1), showing robust, dose-dependent splicing correction.
The data revealed a mean mis-splicing correction of 12.3% at the 5 mg/kg dose and 29.1% at the 10 mg/kg dose, alongside a favorable emerging safety profile. The company also reported its financial results for the fourth quarter and full year ended December 31, 2024.
For Q4 2024, PepGen reported a net loss of $(22,242) thousand, or $(0.68) per share, with research and development expenses at $18,961 thousand. The full year 2024 net loss was $(89,981) thousand, or $(2.85) per share, and the company ended the year with $120,191 thousand in cash, cash equivalents, and marketable securities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.